Drug
Elafibranor
Elafibranor: highest development phase Phase 3, developed by Ipsen. 5 trial records tracked on RxWires.
- Highest phase
- Phase 3
- Developer
- Ipsen
Trials
| Drug | Phase | Indication |
|---|---|---|
| Elafibranor 80mg NCT04526665 | Phase 3 | Primary Biliary Cirrhosis |
| Elafibranor NCT07387549 | Phase 3 | Primary Sclerosing Cholangitis |
| Elafibranor NCT06730061 | Phase 3 | Primary Biliary Cholangitis |
| Elafibranor NCT06016842 | Phase 3 | Primary Biliary Cholangitis (PBC) |
| Elafibranor 80 mg NCT05627362 | Phase 2 | Primary Sclerosing Cholangitis |
Latest
No recent events.
Follow Elafibranor on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.